β-blockers: a new and emerging treatment for melanoma
β-blockers: a new and emerging treatment for melanoma
复制标题
DOI：
10.1701/1022.11152
复制
发表时间：
2012-01-01
影响因子：
--
通讯作者：
Geppetti, Pierangelo
中科院分区：
文献类型：
--
作者：
De Giorgi, Vincenzo;Gandini, Sara;Geppetti, Pierangelo
近年来，关于神经内分泌系统在肿瘤和转移微环境中的作用的研究有了新的进展。这些观察结果表明，最初用于治疗心血管疾病的药物，p -肾上腺素能受体阻滞剂（β受体阻滞剂），可能为控制肿瘤进展提供新的治疗机会。大量观察性研究表明-受体阻滞剂对乳腺癌有保护作用，但最近，在前列腺癌和黑色素瘤等其他癌症中也报道了类似的发现。这些研究的结果表明，使用-受体阻滞剂，而不是其他降压药物，与无病生存期和总生存期的显著增加有关。关于黑色素瘤，De Giorgi等人最近的一项研究表明，每年使用β受体阻滞剂治疗可降低36%的疾病进展风险。这些数据来自前瞻性研究，不能被认为是结论性的，需要通过正在进行的临床试验进行验证。
Recent studies have underlined the innovative theories concerning the role of neuroendocrine system on the tumor and metastasis microenvironment. These observations have suggested the possibility that drugs originally intended for the treatment of cardiovascular disease, the P-adrenergic receptor blockers (beta-blockers), may provide new therapeutic opportunities for the control of tumor progression. A large number of observational studies showed the protective effect of beta-blockers in breast cancer, but more recently, similar findings were also reported in other cancers such as prostate cancer and melanoma. The results of these studies have shown that the use of beta-blockers, but not other antihypertensive drugs, was associated with a significant increase of the disease free survival and of the overall survival. With regard to melanoma, a recent study by De Giorgi et al. showed a 36% reduction in risk of disease progression for each year of treatment with beta-blockers. These data, originating from prospective studies, cannot be considered conclusive and require validation by means of clinical trials that are underway.